Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM86XJG)

Drug Name

MINALRESTAT Drug Info

Synonyms

Minalrestat; WAY-ARI-509; 129688-50-2; Minalrestat [USAN:INN]; Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone, 2-((4-bromo-2-fluorophenyl)-methyl)-6-fluoro-;; 2-(4-Bromo-2-fluorobenzyl)-6-fluorospiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone; Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone, 2-((4-Bromo-2-fluorophenyl)methyl)-6-fluoro-; Bffipt; Minalrestat (2); AC1L4RBZ; Minalrestat (USAN/INN); SCHEMBL49649; CHEMBL273910; BDBM228819; AKOS022180622; SB19712; API0013644

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 190816
CAS Number: CAS 129688-50-2
TTD Drug ID: DM86XJG

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Aldose reductase (AKR1B1)	DTT	AKR1B1	7.436	8.652	9.874	8.066

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diabetic complication

ICD Disease Classification

5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Aldose reductase (AKR1B1)	DTT	AKR1B1	1.08E-20	0.94	1.58

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003006)
2	Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42.